ADIPOQ and diabetes mellitus: Indeed, reinforcing this notion, a recent meta-analysis involving ten randomized controlled trials highlighted that the use of SGLT2i in individuals with type 2 diabetes mellitus was linked to reductions in circulating leptin levels and increases in adiponectin levels [95].